journal article·2025-09Open access

Topoisomerase I Inhibition in ETV4‐overexpressed Non‐Small Cell Lung Cancer Promotes Replication and Transcription Mediated R‐Loop Accumulation and DNA Damage

Jiaxi Zhang, Yan Wang, Shanhu Cao, Shelly M. Xie, Bei Liu, Yimeng Li, Yuqi Hou, Xue Meng, Mingzhu Ruan, Di Bu, Jia Kang, Ruxin Li, Lei Lou, Juan Wang, Lingxiao Xing

Advanced Science· Volume 12· Issue 35

Abstract

Abstract Coordinating transcription and replication via transcription factors (TFs) is a conserved mechanism in higher eukaryotes. The role of TFs in regulating these processes in cancers remains unclear. Here, it is shown that oncogenetic ETS transcription factor ETV4 controls DNA replication through both transcriptional and non‐transcriptional mechanisms in non‐small cell lung cancer (NSCLC). ETV4 localizes to specific DNA replication origins and interacts with the origin recognition complex subunits ORC1 and ORC6 during the G1/S phase, facilitating origin formation. Using quantitative in situ analysis of protein interactions at DNA replication forks (SIRF) assays, it is shown that ETV4 transiently localizes to replication forks in the S phase. It interacts with replicative helicase MCM2 N‐terminal, histone H3, and histone‐chaperone FACT and is involved in histone processing during replication. Additionally, ETV4 transcriptionally regulates key replisome genes MCM2, MCM4, MCM5, MCM10, and ORC1, influencing their expression and recruitment to chromatin. Due to its binding at the origin‐promoter locus like the MCM4 gene, ETV4 overexpression increases R‐loop formation, DNA damage, and cell death under external replication stress induced by topoisomerase I (TOP1) inhibitor. These findings highlight the dual role of ETV4 in replication and transcription and suggest that targeting TOP1 could be a synthetic‐lethal approach in ETV4‐overexpressed lung cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer therapeutics and mechanisms · DNA Repair Mechanisms · Lung Cancer Treatments and Mutations

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology Hebei Medical University Center of Metabolic Diseases and Cancer Research Institute of Medical and Health Science Hebei Medical University Shijiazhuang 050017 P. R. China

Department of Cardiology The First Hospital of Hebei Medical University Hebei Key Laboratory of Heart and Metabolism Department of Biochemistry and Molecular Biology Hebei Medical University Shijiazhuang 050017 P. R. China

Department of Pathology Second Hospital of Hebei Medical University Shijiazhuang 050017 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hebei Province

References (71)

Show source-provided references
1. 10.1146/annurev-biochem-072321-11022810.1146/annurev-biochem-072321-110228 ↗
2. 10.1016/j.cell.2009.10.01510.1016/j.cell.2009.10.015 ↗
3. 10.1016/j.molcel.2009.12.03010.1016/j.molcel.2009.12.030 ↗
4. 10.1101/gad.291336.11610.1101/gad.291336.116 ↗
5. 10.1093/nar/gkw121110.1093/nar/gkw1211 ↗
6. 10.1016/j.molcel.2022.12.02410.1016/j.molcel.2022.12.024 ↗
7. 10.1371/journal.pgen.100044610.1371/journal.pgen.1000446 ↗
8. 10.1101/gr.192799.11510.1101/gr.192799.115 ↗
9. 10.1186/s13059-021-02424-w10.1186/s13059-021-02424-w ↗
10. 10.1038/s41586-022-04803-010.1038/s41586-022-04803-0 ↗
11. 10.1091/mbc.e09-08-070710.1091/mbc.e09-08-0707 ↗
12. 10.1016/j.bbagrm.2015.09.00510.1016/j.bbagrm.2015.09.005 ↗
13. 10.1038/nature0595310.1038/nature05953 ↗
14. 10.1093/nar/gks61710.1093/nar/gks617 ↗
15. 10.1158/0008-5472.CAN-19-103610.1158/0008-5472.CAN-19-1036 ↗
16. 10.1038/nrm328810.1038/nrm3288 ↗
17. 10.1038/nsmb.305510.1038/nsmb.3055 ↗
18. 10.1126/science.aau029410.1126/science.aau0294 ↗
19. 10.1016/j.celrep.2013.02.02810.1016/j.celrep.2013.02.028 ↗
20. 10.1093/nar/gkv02110.1093/nar/gkv021 ↗
21. 10.1016/j.molcel.2018.06.02010.1016/j.molcel.2018.06.020 ↗
22. 10.1101/gad.274183.11510.1101/gad.274183.115 ↗
23. 10.1038/s41586-019-1820-010.1038/s41586-019-1820-0 ↗
24. 10.1038/nrc.2017.2010.1038/nrc.2017.20 ↗
25. 10.1002/mc.2313010.1002/mc.23130 ↗
26. 10.1038/s41388-023-02641-610.1038/s41388-023-02641-6 ↗
27. 10.1126/sciadv.adc944610.1126/sciadv.adc9446 ↗
28. 10.1002/advs.20220561310.1002/advs.202205613 ↗
29. 10.1038/s41388-022-02558-610.1038/s41388-022-02558-6 ↗
30. 10.1016/j.celrep.2017.01.03110.1016/j.celrep.2017.01.031 ↗
31. 10.1101/gad.291948.11610.1101/gad.291948.116 ↗
32. 10.1158/2643-3230.BCD-23-006110.1158/2643-3230.BCD-23-0061 ↗
33. 10.20892/j.issn.2095-3941.2021.013710.20892/j.issn.2095-3941.2021.0137 ↗
34. 10.1038/s41568-020-0290-x10.1038/s41568-020-0290-x ↗
35. 10.1038/s41556-024-01415-w10.1038/s41556-024-01415-w ↗
36. 10.3390/pharmaceutics1408170710.3390/pharmaceutics14081707 ↗
37. 10.1128/MCB.22.4.1036-1048.200210.1128/MCB.22.4.1036-1048.2002 ↗
38. 10.1101/gr.124644.11110.1101/gr.124644.111 ↗
39. 10.1111/cpr.1292010.1111/cpr.12920 ↗
40. 10.1007/s00018-011-0675-910.1007/s00018-011-0675-9 ↗
41. 10.1074/jbc.M70590520010.1074/jbc.M705905200 ↗
42. 10.1093/nar/gkaa75110.1093/nar/gkaa751 ↗
43. 10.1038/s41586-024-08237-810.1038/s41586-024-08237-8 ↗
44. 10.1186/s13578-018-0242-210.1186/s13578-018-0242-2 ↗
45. 10.1074/jbc.M51292120010.1074/jbc.M512921200 ↗
46. 10.1083/jcb.20170912110.1083/jcb.201709121 ↗
47. 10.1038/sj.emboj.760127110.1038/sj.emboj.7601271 ↗
48. 10.1016/j.molcel.2018.08.01010.1016/j.molcel.2018.08.010 ↗
49. 10.1007/978-1-4939-9434-2_310.1007/978-1-4939-9434-2_3 ↗
50. 10.1016/j.molcel.2017.03.00610.1016/j.molcel.2017.03.006 ↗
51. 10.1038/s41586-019-1678-110.1038/s41586-019-1678-1 ↗
52. 10.1038/nsmb.339510.1038/nsmb.3395 ↗
53. 10.1038/nrc197710.1038/nrc1977 ↗
54. Hsiang Y. H. · Cancer Res. · 1989 · 49 · 5077
55. 10.1128/MCB.20.11.3977-3987.200010.1128/MCB.20.11.3977-3987.2000 ↗
56. 10.1126/sciadv.adm819610.1126/sciadv.adm8196 ↗
57. 10.1016/j.molcel.2009.04.01210.1016/j.molcel.2009.04.012 ↗
58. Xu Y. · Mol Cancer · 2024 · 27 · 23
59. 10.15252/embj.201810098610.15252/embj.2018100986 ↗
60. 10.1074/jbc.M41010320010.1074/jbc.M410103200 ↗
61. 10.1146/annurev.biochem.71.110601.13542510.1146/annurev.biochem.71.110601.135425 ↗
62. 10.1016/j.molcel.2025.03.00410.1016/j.molcel.2025.03.004 ↗
63. 10.1038/s41419-024-07081-y10.1038/s41419-024-07081-y ↗
64. 10.1016/S1097-2765(02)00467-710.1016/S1097-2765(02)00467-7 ↗
65. 10.1038/s41586-020-2842-310.1038/s41586-020-2842-3 ↗
66. 10.1073/pnas.080397810510.1073/pnas.0803978105 ↗
67. 10.1016/j.cell.2019.10.00910.1016/j.cell.2019.10.009 ↗
68. 10.1038/s41467-023-39185-y10.1038/s41467-023-39185-y ↗
69. 10.1038/nrm297610.1038/nrm2976 ↗
70. 10.3390/ijms2212616810.3390/ijms22126168 ↗
71. 10.1158/0008-5472.CAN-22-294810.1158/0008-5472.CAN-22-2948 ↗